Table 1: CD200tg, CD200R1KO, and CD200R1KO·CD200tg graft survival in wt/CD200tg mice.

BL/6 donor micea BALB/c recipientsb MST (with range)c Percentage of grafts surviving >75 d Control (wt) wt 9.4 (7–12) 0% Control (wt) CD200tg 48.8 (19–129)** 50% CD200KO wt 7.6 (7–11) 0% CD200KO CD200tg 42.2 (15–121)** 40% CD200R1KO wt 8.8 (7–13) 0% CD200R1KO CD200tg 32.4 (17–88)* 20% CD200R1KO·CD200tg wt 11 (9–25) 0% CD200R1KO·CD200tg CD200tg 33 (19–97)* 30%

Cardiac grafts were obtained from individual donors (all on doxycycline, DOX, for 7 days to induce transgene expression) and transplanted to 10 recipients/group (all maintained on DOX). cGrafts were palpated daily for evidence of rejection; MST indicates mean (graft) survival time in days. * compared with 1st row; ** compared with CD200R1KO or CD200R1KO·CD200tg grafts transplanted to CD200tg (rows 6 and 8).